Bet-inhibitor - OmicsDI

Show results for

Unknown (673)
Genomics (577)
Transcriptomics (378)
Proteomics (24)
Other (17)
Clinical (3)
Methylation profiling (1)
Metabolomics (1)

Organisms

Homo sapiens (397)
Mus musculus (115)
Aerococcus urinae NBRC 15544 = CCUG 36881 (19)
Alteromonadales (19)
Bacteria (19)
Canis lupus familiaris (19)
Carya cathayensis (19)
Ectopseudomonas oleovorans CECT 5344 (19)
Ensifer adhaerens (19)
Enterococcus faecalis (19)
Globicatella sanguinis (19)
Halictus scabiosae (19)
Histomonas meleagridis (19)
Human immunodeficiency virus 1 (19)
Mesocricetus auratus (19)
Methylohalobius crimeensis 10Ki (19)
Mus musculus (19)
Rattus norvegicus (4)
Drosophila melanogaster (3)
Papio hamadryas (2)
Saccharomyces cerevisiae (2)
Influenza A virus (A/WSN/1933(H1N1)) (1)
Saccharomyces cerevisiae W303 (1)
Bacillus methanolicus (1)
Schizosaccharomyces pombe (1)
Bacillus subtilis (1)
Caenorhabditis elegans (1)
Plasmodium falciparum (1)
Triticum aestivum (1)
synthetic construct (1)

Organisms

Homo sapiens (328)
Mus musculus (83)
Rattus norvegicus (4)
Drosophila melanogaster (2)

Repository

ENA (454)
geo (379)
biostudies-arrayexpress (139)
pride (19)
MassIVE (3)
iProX (2)
EGA (1)
MetaboLights (1)

Tissue

Cell culture (9)
Brain (4)
Blood (2)
Blood cell (1)
Epithelial cell (1)
Fibroblast (1)
Granulocyte (1)
Hematopoietic progenitor cell antigen CD34 (human) (1)
Permanent cell line cell (1)
T cell (1)

Disease

Carcinoma (1)
Colorectal Neoplasms (1)
Neoplasms (1)
Acute leukemia (1)
Brain glioblastoma multiforme (1)
Essential thrombocythemia (1)
Multiple myeloma (1)
Myelofibrosis (1)
Myeloproliferative neoplasm (1)
Pancreatic cancer (1)

Technology Type

Mass Spectrometry (19)
Shotgun proteomics (9)
Bottom-up proteomics (8)
SWATH MS (5)
Mass spectrometry (1)

Instrument Platform

NextSeq 500 (8)
Illumina HiSeq 2500 (5)
TripleTOF 5600 (3)
NextSeq 550 (2)
MoFlo XDP (Beckman Coulter) or a FACSAria II (Becton Dickinson) (1)
Fluidigm C1 autoprep system (1)
Gene Titan (1)
Illumina Genome Analyzer IIx (1)
Illumina MiSeq (1)
Illumina NovaSeq 6000 (1)
Liquid Chromatography MS - alternating - reverse-phase (1)
Liquid Chromatography MS - alternating - hilic (1)

Publication Date

2022 (44)
2016 (44)
2020 (42)
2025 (42)
2015 (41)
2026 (39)
2024 (36)
2013 (35)
2017 (34)
2023 (34)
2021 (33)
2018 (32)
2019 (27)
2014 (21)
2012 (12)
2010 (10)
2011 (9)
2007 (4)
2009 (2)
2008 (1)
2006 (1)

Metabolite Name

Hexenoylcarnitine (Car(6:1)) (1)
4-(Dimethylamino)pyridine (1)
1-(1Z-Octadecenyl)-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphocholine (1)
N-Oleoyl-D-erythro-sphingosylphosphorylcholine (1)
Arsenobetaine (1)
L-Norvaline (1)
Oxotetradecadienoylcarnitine (Car(14:3-O)) (1)
1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine (1)
Imiquimod (1)
[(Aminocarbonyl)(methyl)amino]acetic acid (1)
2-(2-Aminoethoxy)acetic acid (1)
Alpinetin (1)
2-Amino-3-methyl-imidazo[4,5-f]quinoline (IQ) (1)
1-Docosahexaenoyl-2-stearoyl-sn-glycero-3-phosphocholine (1)
Dihydrotachysterol (1)
Azeliragon (1)
Picoline (1)
Aminopicoline (1)
Tiglylcarnitine (Car(5:1)) (1)
Cysteine S-sulfate (1)
Fenobucarb (1)
Dibenzylamine (1)
Pyrimethanil (1)
N-Nitrosopyrrolidine (1)
Oxooctanoylcarnitine (Car(8:1-O)) (1)
.beta.-D-Glucopyranosiduronic acid, 4-(7-hydroxy-4-oxo-4H-1-benzopyran-3-yl)phenyl (1)
Tetradecenedioylcarnitine (Car(14:1-O2)) (1)
Perifosine (1)
1-Octadecylamine (1)
1-O-Hexadecyl-2-O-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glyceryl-3-phosphorylcholine (1)

First Public Date

2024 (49)
2020 (49)
2019 (45)
2022 (43)
2025 (42)
2023 (38)
2021 (38)
2017 (32)
2026 (31)
2018 (26)
2014 (24)
2016 (16)
2015 (15)
2013 (6)

Study status

Terminated (1)
Recruiting (1)
Not yet recruiting (1)

Study type

Transcription profiling by array (67)
RNA-seq of coding RNA (22)
ChIP-seq (21)
ChIP-chip by tiling array (9)
Transcription profiling by tiling array (4)
RNA-seq of coding RNA from single cells (4)
Interventional (3)
Unknown experiment type (2)
Other (2)
Translation profiling (1)
Animal - High-throughput sequencing (1)
Cell line - High-throughput sequencing (1)
Capture-C (1)
DNA-seq (1)
Methylation profiling by high throughput sequencing (1)
RNA-seq of total RNA (1)
RNA-seq of non coding RNA (1)

Release Date

2022 (83)
2021 (71)
2015 (66)
2020 (63)
2016 (63)
2023 (61)
2019 (60)
2018 (59)
2017 (52)
2024 (47)
2013 (47)
2025 (45)
2014 (34)
2012 (18)
2026 (11)
2011 (10)
2010 (10)
2007 (5)
2009 (2)
2006 (2)
2008 (1)

Lab affiliation

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02215, USA (3)
Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX (3)
The Drug Discovery Lab, Mary S. Easton Center for Alzheimer’s Disease Research, Department of Neurology, David Geffen School of Medicine, 710 Westwood Plaza, University of California Los Angeles, Los Angeles, CA 90095, USA (2)
Core Unit Proteomics, Berlin Institute of Health at Charite - Universitaetsmedizin Berlin and Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany (1)
Director, Proteomics and Metabolomics Facility, Center for Open Research Resources and Equipment, University of Connecticut, Storrs, CT, USA (1)
Facutly of Science, University of Geneva (1)
Georgetown University, USA (1)
IRIC-Université de Montréal (1)
Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Zurich, Switzerland (1)
Leukemia Department, MD Anderson Cancer Center, Houston, TX 77030 (1)
Maj Institute of Pharmacology, Polish Academy of Sciences, Department of Pharmacology, Laboratory of Pharmacology and Brain Biostructure, Smetna Str. 12, 31-343 Krakow, Poland (1)
Section for Translational Surgical Oncology and Biobanking, Department of Surgery, University of Lübeck and University Hospital Schleswig-Holstein, Campus Lübeck, Germany (1)
University Medical Center, Department of Clinical Chemistry, Core Facility Proteomics (1)
University of Geneva, Switzerland (1)

Location

United States (2)
United Kingdom (1)
Spain (1)

Keyword

INCB057643 (1)
Azacitidine (1)
Pembrolizumab (1)
Antineoplastic Agents, Immunological (1)
Antibodies (1)
Immunoglobulins (1)
Antibodies, Monoclonal (1)
CRC (1)
Capecitabine (1)
Cetuximab (1)

Previous page
1 / 168
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 168
Next page

Sort by:

Relevance

Page size

Streptococcus anginosus promotes hepatocellular carcinoma progression and BET inhibitor resistance by inducing BRD4 lactylation

Hepatocellular carcinoma (HCC) is a highly aggressive form of carcinoma with a poor prognosis. Diagnostic markers and potential therapeutic targets for HCC are urgently needed. Here, we demonstrate that fecal microbiota transplantation (FMT) using stool samples from HCC patients significantly pro...

2025-12-05 | MTBLS12398 | MetaboLights

Genome wide expression analysis of BET inhibitor resistance

Bromodomain and Extra Terminal protein (BET) inhibitors are first-in-class targeted therapies that deliver a new therapeutic paradigm by directly targeting epigenetic readers. Early clinical trials have shown significant promise especially in acute myeloid leukaemia (AML)3; therefore the evaluation ...

ORGANISM(S): Mus musculus

2015-09-15 | E-GEOD-63575 | biostudies-arrayexpress

Genome wide expression analysis of BET inhibitor resistance [RNA-seq]

Bromodomain and Extra Terminal protein (BET) inhibitors are first-in-class targeted therapies that deliver a new therapeutic paradigm by directly targeting epigenetic readers1,2. Early clinical trials have shown significant promise especially in acute myeloid leukaemia (AML)3; therefore the evaluati...

ORGANISM(S): Mus musculus

2015-09-15 | E-GEOD-63681 | biostudies-arrayexpress

ChIP of BET proteins in iBET resistance [ChIP-seq]

Bromodomain and Extra Terminal protein (BET) inhibitors are first-in-class targeted therapies that deliver a new therapeutic paradigm by directly targeting epigenetic readers1,2. Early clinical trials have shown significant promise especially in acute myeloid leukaemia (AML)3; therefore the evaluati...

ORGANISM(S): Mus musculus

2015-09-15 | E-GEOD-63682 | biostudies-arrayexpress

Expression data from non-small cell lung cancer cell line DV90 after Bromodomain and extra terminal domain (BET) inhibitor JQ1 treatment

Bromodomain and extra terminal domain (BET) inhibition reduces occupancy of BET-family proteins at promoter and enhancer sites resulting in changes in the transcription of specific genes. We used microarray profiling to investigate the transcriptional changes induced by BET inhibitor JQ1 treatment i...

ORGANISM(S): Homo sapiens

2016-03-31 | E-GEOD-75960 | biostudies-arrayexpress

BET Protein Inhibitor JQ1 Induces Cell Cycle Arrest in Mesenchymal Stem Cells

Efficacy and safety of anticancer drugs are traditionally studied using cancer cell lines and animal models. Recently, a potential anticancer agent, JQ1, an inhibitor of bromodomain and extra terminal (BET) protein, has been shown to promote apoptosis of cancerous cells by arresting them in G1 phase...

ORGANISM(S): Homo sapiens

2016-02-12 | E-GEOD-70577 | biostudies-arrayexpress

Blockade of oncogenic IkappaB kinase activity in ABC DLBCL by small molecule BET protein inhibitors

In the activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL), NF-kappaB activity is essential for viability of the malignant cells and is sustained by constitutive activity of IkappaB kinase (IKK) in the cytoplasm. Here, we report an unexpected role for the bromodomain and ext...

ORGANISM(S): Homo sapiens

2014-08-01 | E-GEOD-58791 | biostudies-arrayexpress

Gene expression analysis of B-ALL cells treated with BET inhibitor

Two human acute lymphoblastic leukemia cell lines were treated with a BET bromodomain inhibitor that blocks BET association with chromatin. These cell lines, MHH-CALL4 and MUTZ-5, each carry translocation of the CRLF2 gene into the IgH locus, and their growth was found to be susceptible to BET inhib...

ORGANISM(S): Homo sapiens

2012-08-09 | E-GEOD-39995 | biostudies-arrayexpress

BET inhibitor UM-002 reduces GBM proliferation and invasion

PRJNA723881 | ENA

Transcripitional profiling of Huh7 cells after MAT2A inhibitor (FIDAS-5) or BET bromodomain inhibitor (JQ1) treatment

PRJNA762980 | ENA